Epidemiologic Evaluation of Human Papillomavirus Type Competition and the Potential for Type Replacement Post-Vaccination.

Autor: Joseph E Tota, Mengzhu Jiang, Agnihotram V Ramanakumar, Stephen D Walter, Jay S Kaufman, François Coutlée, Harriet Richardson, Ann N Burchell, Anita Koushik, Marie Hélène Mayrand, Luisa L Villa, Eduardo L Franco

Publikováno v: PLoS ONE, Vol 11, Iss 12, p e0166329 (2016)

Millions of women have been vaccinated with one of two first-generation human papillomavirus (HPV) vaccines. Both vaccines remain in use and target two oncogenic types (HPVs 16 and 18); however, if these types naturally compete with others that are n

Externí odkaz: https://doaj.org/article/3ed9c8b1b93943cfad18add79e9ec2ae

Efficacy and safety of a self-applied carrageenan-based gel to prevent human papillomavirus infection in sexually active young women (CATCH study): an exploratory phase IIB randomised, placebo-controlled trialResearch in context

Autor: Cassandra Laurie, Mariam El-Zein, Sarah Botting-Provost, Joseph E. Tota, Pierre-Paul Tellier, François Coutlée, Ann N. Burchell, Eduardo L. Franco

Publikováno v: EClinicalMedicine, Vol 60, Iss , Pp 102038- (2023)

Summary: Background: Carrageenan demonstrated potent anti-HPV (human papillomavirus) activity in vitro and in animal models. The Carrageenan-gel Against Transmission of Cervical Human papillomavirus trial’s interim analysis (n = 277) demonstrated a

Externí odkaz: https://doaj.org/article/997e53be9b4f4e25af0ad9bbe554cbba

Incidence of cervical precancerous lesions and cervical cancer in Denmark from 2000 to 2019: Population impact of multi-cohort vaccination against human papillomavirus infection

Autor: Linea Landgrebe Ring, Christian Munk, Michael Galanakis, Joseph E. Tota, Louise T. Thomsen, Susanne K. Kjaer

Publikováno v: Ring, L L, Munk, C, Galanakis, M, Tota, J E, Thomsen, L T & Kjaer, S K 2023, ' Incidence of cervical precancerous lesions and cervical cancer in Denmark from 2000 to 2019 : Population impact of multi-cohort vaccination against human papillomavirus infection ', International Journal of Cancer, vol. 152, no. 7, pp. 1320-1327 . https://doi.org/10.1002/ijc.34328

In Denmark, vaccination against human papillomavirus (HPV) has been implemented in the children's vaccination program (January 2009) and in multiple catch-up cohorts (October 2008 in girls 13-15 years and in August 2012 in women up to 27 years). In t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cb3e0ab87f51617bffb43d1f172b63b
https://pubmed.ncbi.nlm.nih.gov/36250312

Defining benchmarks for tolerable risk thresholds in cancer screening: Impact of HPV vaccination on the future of cervical cancer screening

Autor: Eduardo L. Franco, Joseph E. Tota, Sandra D. Isidean

Publikováno v: International Journal of Cancer

The performance of cervical cancer screening will decline as a function of lower disease prevalence—a consequence of successful human papillomavirus (HPV) vaccination. Replacement of cytology with molecular HPV testing as the primary screening test

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24d6696dc3ea10125998933d3d781010
https://doi.org/10.1002/ijc.33178

Real-world impact and effectiveness assessment of the quadrivalent HPV vaccine: a systematic review of study designs and data sources

Autor: Mari Nygård, Marc Baay, Wei Wang, Joseph E. Tota, Christine Velicer, Thomas Verstraeten, Anna R. Giuliano, Suzanne M. Garland, Anushua Sinha, Karin Sundström, Jozica Skufca, Smita Kothari

Publikováno v: Expert review of vaccines. 21(2)

Introduction Vaccine effectiveness and impact studies are typically observational, generating evidence after vaccine launch in a real-world setting. For human papillomavirus (HPV) vaccination studies, the variety of data sources and methods used is p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87b13187ea859ba218230630ff663114
https://pubmed.ncbi.nlm.nih.gov/34845951